This conference has been withdrawn from the 2020 conference schedule
As you are aware, coronavirus is having a global impact and the World Health Organization and the Centers for Disease Control have instituted recommendations that include social distancing and cancelling conferences and large gatherings. Since safety of our attendees is always GRC's highest priority, the GRC Board of Trustees has decided to withdraw this conference and it will be rescheduled for 2022. This decision was made out of an abundance of caution and to alleviate the concerns of our conference communities that are scheduled to meet in this timeframe.
Technological advances have revolutionized our ability to prevent, diagnose and treat a broad spectrum of diseases. Both inherited and acquired genetic alterations have been detected that enhance our understanding of the pathobiology of many illnesses. The accumulation of data and the associated knowledge gained is being procured at an astounding pace. Cancer is the paradigm and the application of these discoveries has had a profound impact. In both blood cancers and solid tumors new strategies are emerging that prolong life and decrease morbidity. We now recognize that there are several hundred distinct malignancies and within each subset unique alterations that produce potential biomarkers and treatment targets. It is now possible to define high risk populations, develop meaningful early detection approaches, maximize the effectiveness of therapy, ameliorate toxicity and improve survivorship. The foundation has been established for remarkable progress that will extend to other medical conditions.
This conference provides a forum for leading figures in the field to share their most recent work relevant to this topic. Ample time will be devoted to discussion, idea-exchanges, and social interactions with participants. The Hong Kong University venue provides the ideal environment for scientific lectures and informal dialogue. Presentations will range from basic to translational investigations that illustrate the current state of knowledge and future directions. Sessions include Population Sciences, Advanced Diagnostics, Metabolism, Non-coding RNA and Epigenetics, Integrated Omics Applications, Biomedical Engineering, Immuno-therapeutics and Cellular Therapeutics with an emphasis toward precision medicine. Participants will be exposed to cutting edge research and the practical application of these observations for the benefit of humanity.